Cargando…

OR16-06 Age-Associated Local GH Promotes Colon Neoplasia

Colon polyp and cancer frequency increase with age, yet little is known about age-related mechanisms underlying development of these neoplasms. Defective DNA damage response and accumulation of unrepaired DNA damage can trigger genomic instability and cellular transformation. Patients with acromegal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chesnokova, Vera M, Zonis, Svetlana, Apostolou, Nasia, Hannah, Estrada Q, Knott, Simon, Wawrowsky, Kolja, Ben-Shlomo, Anat, Barrett, Robert, Gorbunova, Vera, Karalis, Katia, Melmed, Shlomo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208399/ http://dx.doi.org/10.1210/jendso/bvaa046.1474

Ejemplares similares

GH Is a Component of SASP in Aging Tissue
por: Chesnokova, Vera M, et al.
Publicado: (2021)

THU045 WIP1 Phosphatase Is A Novel Specific Target For Epithelial GH Action
por: Apaydin, Tugce, et al.
Publicado: (2023)

MON-475 Growth Hormone Induces Colon Tissue DNA Damage Independently of IGF-1
por: Chesnokova, Vera, et al.
Publicado: (2019)

Local non-pituitary growth hormone is induced with aging and facilitates epithelial damage
por: Chesnokova, Vera, et al.
Publicado: (2021)

MON-459 ONO-5788, a Novel Oral Small Molecule Somatostatin Receptor Type-2 (SST2) Agonist, Attenuates GH Hypersecretion in Human GH-Secreting, Pituitary Adenoma-Derived Cells
por: Zhou, Cuiqi, et al.
Publicado: (2019)

Lineage-Specific Restraint of Pituitary Gonadotroph Cell Adenoma Growth
por: Chesnokova, Vera, et al.
Publicado: (2011)

GH and Senescence: A New Understanding of Adult GH Action
por: Chesnokova, Vera, et al.
Publicado: (2021)

OR06-04 Tissue-Specific Tumorigenesis in Multiple Endocrine Neoplasia Type I
por: Gardiner, Juliet C
Publicado: (2020)

Pituitary Somatotroph Adenoma Cell-Derived Exosomes: Characterization of Novel Non-Hormonal Functions
por: Zhou, Cuiqi, et al.
Publicado: (2021)

SUN-442 EGFR/ErbB2 Targeted Therapy for Aggressive Prolactinomas
por: Cooper, Odelia, et al.
Publicado: (2019)

OR27-4 Placebo-Controlled and Open-Label Extension Study of a Novel Hepatic-Targeted Antisense Cimdelirsen (IONIS-GHR-LRx) Under Investigation in Acromegaly Patients
por: Bhanot, Sanjay, et al.
Publicado: (2022)

The Pharmacological Burden of Comorbidities in Acromegaly
por: Fleseriu, Maria, et al.
Publicado: (2021)

THU061 Treatment Patterns In Acromegaly: Analysis Of Real-World US Insurance Claims From The MarketScan(®) Database
por: Fleseriu, Maria, et al.
Publicado: (2023)

THU071 Key Device Attributes For Injectable SRL Therapy In Acromegaly And NETs To Aid Clinical Decision Making
por: de Herder, Wouter W, et al.
Publicado: (2023)

OR06-06 Pituitary Tumors and Immortalized Cell Lines Generated by Cre-Inducible Expression of SV40 T-Antigen
por: Mortensen, Amanda Helen, et al.
Publicado: (2020)

A Case With Adult GH Deficiency Complicated With Osteogenesis Imperfecta: Effect of GH Replacement on Bone Mineral Density
por: Taguchi, Tomomi, et al.
Publicado: (2021)

PMON47 Fluid restriction reduces hyponatremia and hospital readmission rates following pituitary surgery
por: Mamelak, Adam, et al.
Publicado: (2022)

OR23-07 Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study of Oral Octreotide Capsules in Adult Patients with Acromegaly
por: Samson, Susan Leanne, et al.
Publicado: (2020)

MON-LB55 Biochemical Control of Most Patients Reverting to Injectable Long-Acting Somatostatin Receptor Ligands Is Achieved After One Dose: Results From the Phase 3, Randomized, Double Blind, Placebo-Controlled Optimal Study
por: Fleseriu, Maria, et al.
Publicado: (2020)

PMON166 Safety Comparison of 40- vs 60-mg/day Doses of Oral Octreotide Capsules for Treatment of Acromegaly in the CHIASMA OPTIMAL Trial
por: Elenkova, Atanaska, et al.
Publicado: (2022)

LBMON178 2nd Year Outcomes Of The Open-label Extension Of Chiasma Optimal, A Phase 3 Study Of Oral Octreotide Capsules In Acromegaly
por: Samson, Susan, et al.
Publicado: (2022)

OR06-01 The Role of Germline Defects in Cushing’s Disease
por: Hernández-Ramírez, Laura C, et al.
Publicado: (2020)

OR16-1 Best of The Journal of Clinical Endocrinology & Metabolism: Macimorelin as a Diagnostic Test for Adult GH Deficiency
por: Garcia, Jose, et al.
Publicado: (2019)

MON-323 IGF-I Variability and Its Association with Demographic and Clinical Characteristics in Patients with Acromegaly Treated with Injectable Somatostatin Receptor Ligands (SRLS); Results from an International Prospective Phase III Study
por: Samson, Susan Leanne, et al.
Publicado: (2020)

MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

MON-297 Withdrawal from Long-Acting Somatostatin Receptor Ligand Injections in Adult Patients with Acromegaly: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

THU057 Predictors Of Response To Oral Octreotide Capsules In Patients With Acromegaly In A Large Prospective International Trial
por: Fleseriu, Maria, et al.
Publicado: (2023)

MON-473 Growth Hormone (GH) Impacts the Gut Microbial Profile: the Presence of Unique Bacterial Genera in Mouse Lines with Altered GH Action
por: Jensen, Elizabeth, et al.
Publicado: (2019)

MON-265 Once-Weekly Somapacitan in Japanese Adults with GH Deficiency Was Well Tolerated, with Similar Efficacy to Daily GH: A Randomized Trial
por: Otsuka, Fumio, et al.
Publicado: (2020)

MON-314 Analysis of Adverse Events in Adult Patients with Acromegaly Receiving Oral Octreotide Capsules: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
por: Labadzhyan, Artak, et al.
Publicado: (2020)

OR32-4 Diagnostic Performance of Macimorelin vs the Insulin Tolerance Test (ITT) in 140 Patients at Varying Growth Hormone (GH) Cutpoints: A Post Hoc Analysis
por: Garcia, Jose, et al.
Publicado: (2019)

SAT-255 Pituitary Adenoma With TSH and GH Co Secretion
por: Riquelme, Romina, et al.
Publicado: (2020)

Somatostatin, as a Bridge Between the GH-Axis and the Gth-Axis
por: Mizrahi, Naama, et al.
Publicado: (2021)

RF13 | PMON159 Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly: MPOWERED Trial Open-Label Extension Phase
por: Fleseriu, Maria, et al.
Publicado: (2022)

MON-LB57 Impact of Imputation Method and Response Cutoffs on Results From the Phase 3 OPTIMAL Study of Oral Octreotide Capsules in Adult Patients With Acromegaly
por: Samson, Susan Leanne, et al.
Publicado: (2020)

TSH, GH, and Prolactin Producing Pituitary Adenoma: An Unusual Case Presentation
por: Manrique, Helard Andres, et al.
Publicado: (2021)

PMON129 Pituitary Adenoma Co-Secreting GH, Prolactin and ACTH
por: Wilson, Sarah, et al.
Publicado: (2022)

OR06-1 Melanocortins Act on Kiss1 Neurons to Regulate Reproduction in Females
por: Talbi, Rajae, et al.
Publicado: (2019)

OR06-03 Serotonin Regulates Corticotroph Tumor Cell Proliferation and ACTH Secretion
por: Zhang, Dongyun, et al.
Publicado: (2020)

PMON60 Growth Hormone (GH) Replacement Therapy (GHRT) in Patients with Adult GH Deficiency (AGHD) Aged ≥60 Years: Data from NordiNet® IOS and the ANSWER Program
por: Biller, Beverly, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_91s1lftrcaoo22ocpkp6r7ps7v